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Ricin, a highly potent toxin produced by castor beans, is classified by the Centers for Disease Control and Prevention as a level B biothreat because it is easily produced, readily available, and highly stable. There have been >750 cases of documented ricin intoxication in humans. There is no approved vaccine for ricin. Ricin contains a lectin-binding B chain and a ribotoxic A chain (RTA). In addition to its ribotoxic site, we have identified a separate site on RTA that is responsible for inducing vascular leak syndrome (VLS) in humans. We have generated a recombinant RTA with two amino acid substitutions that disrupt its ribotoxic site (Y80A) and its VLS-inducing site (V76M). This mutant recombinant RTA (named RiVax) was expressed and produced in Escherichia coli and purified. When RiVax was injected i.m. into mice it protected them against a ricin challenge of 10 LD50s. Preclinical studies in both mice and rabbits demonstrated that RiVax was safe. Based on these results, we have now conducted a pilot clinical trial in humans under an investigational new drug application submitted to the Food and Drug Administration. In this study, three groups of five normal volunteers were injected three times at monthly intervals with 10, 33, or 100 g of RiVax. The vaccine was safe and elicited ricinneutralizing Abs in one of five individuals in the low-dose group, four of five in the intermediate-dose group, and five of five in the high-dose group. These results justify further development of the vaccine.
R
icin is an extremely lethal toxin produced by castor beans (1-3). It contains a ribotoxic A chain (RTA) and a cellbinding B chain (1, (4) (5) (6) (7) (8) (9) (10) . It is widely available, easy to purify, and highly stable as a liquid or powder (11) . The estimated lethal dose of ricin in humans is 1-10 g͞kg when delivered as an aerosol or by injection (11) . In earlier studies, the lethal dose of ricin administered by ingestion was reported to be much higher, i.e., 1-2 g (approximately a teaspoon of powder) (11, 12) . Ricin represents a potential agent for use in biological warfare and is classified by the Centers for Disease Control and Prevention as a level B biothreat (13) . There is no approved vaccine for ricin.
We have developed a recombinant RTA vaccine (14, 15) in which only two amino acids in the protein have been genetically engineered to inactivate both the well known ribotoxic site (5, (16) (17) (18) and the recently identified VLS-inducing site (19) . The mutant protein, Y80A͞V76M or RiVax, lacks both toxic activities but retains all of the immunodominant epitopes recognized by a panel of mAbs (14) . Three doses of 1-10 g each administered i.m. to mice in the absence of adjuvant protected them from a subsequent challenge with 10 LD 50 s of ricin (14, 15) . A formal toxicology study in rabbits revealed no toxicity (14) .
To determine whether RiVax is also safe and immunogenic in humans, we have carried out a pilot clinical trial in which three groups of five volunteers each were vaccinated. Individuals received three monthly i.m. injections of either 10 g (group 1), 33 g (group 2), or 100 g (group 3) of RiVax without adjuvant. The volunteers were monitored for side effects and for the generation of both anti-RTA Abs and ricin-neutralizing Abs. In this report, we present the results of this trial.
Results
RiVax. RiVax was produced, vialed, and tested in our good manufacturing practice laboratory. Each production run was assigned a lot number, and each lot was tested for release and, at monthly intervals, for stability. Four different lots were used for the vaccinations. The certificate of analysis showing the release criteria is presented in Table 1 .
Entry and Vaccination of Volunteers.
This was an open label, intergroup dose escalation trial in normal volunteers recruited at the University of Texas Southwestern Medical School. Volunteers had to be between 18 and 30 years of age, be not pregnant and on birth control if female, have normal medical histories, including no recognized immunodeficiencies or concurrent treatments with immunosuppressive agents, and have no significant concurrent medical conditions. Volunteers with seasonal allergies were permitted to enter the study. Approximately 1-2 weeks before entering the study, sera from the volunteers were tested for Abs against RTA and were required to be negative before entry. Physical examinations, complete blood counts, routine blood chemistries, urinalysis, and tests for HIV, hepatitis B virus, hepatitis C virus, and pregnancy were also performed. Physical examinations, complete blood counts, routine blood chemistries, and urinalyses were also performed just before each injection (day 0), and on days 1, 3, and 7 after each injection. Pregnancy tests were also performed before each vaccination.
There were three dose levels with five volunteers per dose level. Each volunteer received three identical doses of the vaccine i.m. at monthly intervals. The individual doses were 10, 33, or 100 g. Entry at the next higher dose level could not begin until all five volunteers from the previous dose level had (i) received their second dose of vaccine and (ii) been followed for 1 week, and (iii) until the study monitor had confirmed that the dose was safe. If two cases of grade 2 toxicity occurred at any dose level, study enrollment was to be stopped pending further review.
Volunteers were required to complete a patient diary detailing side effects, injection-site reactions (heat, pain, erythema, and induration), acute pain assessment, limitation of arm movement, local itching͞tenderness, and s.c. nodule formation. Toxicities were graded according to the Food and Drug Administration's Draft Guidelines for Toxicity Grading in Healthy Volunteers. Sera for the measurement of anti-RTA Abs were obtained immediately before each i.m. injection, on day 70 (14 days after the last vaccination), and at intervals thereafter as long as they remained positive. Total Abs against RTA were measured by RIA (16) , and neutralizing titers were measured by adding dilutions of sera to ricin and then adding the mixture to cells in vitro. We also determined whether when the sera were mixed with ricin and injected into mice, they were protected from ricin intoxication.
All volunteers signed consent forms, and the study was approved by the local institutional review board. The study was conducted under an investigational new drug application submitted to the Food and Drug Administration.
Demographics. The demographics of the volunteers are shown in Table 2 . Volunteers were between 22 and 29 years of age, and the group of 15 included 12 males and 3 females from five different ethnic groups (Caucasian, Indian, Asian, Middle Eastern, and Hispanic). Vaccinations and tests were given on schedule with three exception: volunteer 6 was vaccinated on days 0, 35, and 71; volunteer 5 was vaccinated on days 0, 28, and 140; and volunteer 14 was vaccinated on days 0, 28, and 70, and his serum was collected 21 days later.
Toxicity. As reported in Table 3 , none of the 15 volunteers experienced a grade 3 or 4 symptomatic toxicity in this study. Two experienced grade 2 toxicities. The toxicities were those often associated with i.m. injections of approved vaccines (20) (21) (22) (23) .
Twelve volunteers reported transient side effects during the 7 days after vaccination. These included mildly sore͞tender arms, redness, or warmness at the injection site. Four volunteers reported mild headaches, and one reported mild nausea. Four of the five volunteers who had a history of allergies or sinus infection reported sore throats, congestion, or sinus infection during the study. One of these volunteers reported a grade 2 sore throat and headache after the third vaccination. The only other grade 2 event was fatigue after the third vaccination in volunteer 9 who had a chronically elevated bilirubin and seemed to experience more reactions to all three vaccinations than any other volunteer (except volunteer 5), including mild chills, myalgia, and warm feeling at the site of injection.
Laboratory values remained normal with several exceptions. (i) The most common laboratory abnormality was a modest increase in creatine phosphokinase (CPK) values. Volunteer 13 (group 3) had an elevated CPK before and after the first injection. Volunteers 5 (group 1) and 9 (group 2) had elevated CPKs [2.7-and 1.2-fold the upper limit of normal (ULN)] on one occasion each, after dose 1. Volunteers 8 (group 2) and 14 (group 3) had elevated CPKs (both 1.5-fold the ULN) after dose 2. Volunteers 11, 12, and 13 (group 3) had modest elevations in CPKs (2.8-, 1.8-, and 1.7-fold the ULN) before and͞or after the third vaccination. (ii) Volunteer 12 had very modestly elevated alanine transaminase (1.4-fold the ULN) after the third vaccination. (iii) Volunteer 9 had Gilbert's syndrome and thus had mildly elevated bilirubin values throughout the study. None of these elevations were associated with clinical signs or symptoms, and they were most likely due to the muscle inflammation resulting from the reaction to the i.m. vaccination.
In contrast to the modest increases in CPKs in these seven volunteers, volunteer 4 (group 1) had a CPK elevation that was 30-fold the ULN on the day of his third dose, just before being vaccinated. His alanine transaminase value was 1.9-fold the ULN before study entry, and it remained elevated throughout the study, including day 7 after the third vaccination. His alanine transaminase (2.8-fold the ULN) and aspartate aminotransferase (3.8-fold the ULN) were elevated before his third vaccination. The elevated CPK and aspartate aminotransferase decreased steadily after the third vaccination, returning to normal levels by day 7. The volunteer denied excessive exercise and the use of either recreational or prescribed drugs; he was asymptomatic. We consider it unlikely that these abnormal values were related to the vaccinations.
Titers of Anti-RTA Ab. An RIA was used to measure Ab titers immediately before entry, before each vaccination, 2 weeks after the third vaccination, and at intervals thereafter. The preentry sera were used as negative controls for each postvaccination sample. Each assay was carried out twice. As shown in Table 4 , anti-RTA levels at day 70 varied from 0.97-22.6 g͞ml and were not related to the dose of vaccine given. Indeed, the individual in group 1 who made Ab by day 70 had a higher titer than any individual in group 3. Hence, the titers at 2 weeks after the third injection were unrelated to the dose given. Of these seroconverters, one in group 2 and two in group 3 had measurable antibody titers just prior to receiving their third vaccination. The titers of Ab lasted from 14-127 days after the third vaccination, and the longevity of the response was unrelated to the vaccine dose given (Fig. 1) . The data suggest that the optimal dose tested in this study in the absence of adjuvant and using this dose regimen was between 33 g three times and 100 g three times.
Titers of Neutralizing Abs. Once the levels of anti-RTA Abs were determined, the positive sera were then tested twice for their ability to neutralize ricin. Briefly, dilutions of sera with known Ab titers were mixed with the IC 90 of ricin (5 ϫ 10 Ϫ10 M) for Daudi cells (15) . The mixture was added to the cells, and the inhibition of protein synthesis was measured. Controls included sera alone, ricin alone, or ricin mixed with a known amount of normal or immune (ricin-neutralizing) rabbit sera. As described in the Materials and Methods, the lower the g͞ml of Ab necessary to neutralize ricin, the more potent the Ab and, hence, the higher the titer. As shown in Table 4 , all of the volunteers with anti-RTA Ab also had ricin-neutralizing Ab in their sera 2 weeks after the third vaccination. The neutralization titer for the only seroconverter in group 1 was 0.53 g͞ml, and the ranges of titers in groups 2 and 3 were 0.27-1.75 g͞ml and 0.13-1.40 g͞ml, respectively. Hence, the levels of neutralizing Ab were not related to the dose of the vaccine given. Finally, there was no correlation between the anti-RTA Ab titers determined by RIA and the neutralizing Ab titers. Of interest, the individual whose Ab had the most robust neutralizing activity received his third vaccination 112 days after the second vaccination, whereas all of the other volunteers received theirs 28-42 days after the second vaccination.
Passive Protection Experiments. To determine whether the Abs made by the volunteers could passively protect mice against a lethal ricin challenge, positive sera from the individuals in group 2 and group 3 were pooled (separately by group), and the globulins were concentrated by precipitation with 50% saturated ammonium sulfate, redissolved, and dialyzed. Mice were injected with a mixture of the globulins and ricin. They were monitored for weight loss and death. The highest dose of serum used was based on the relationship between the previously determined neutralizing titer in the in vitro assay and the amount needed to protect mice from a ricin challenge; lower doses were also used to estimate the precise protective dose. Controls included mice injected with ricin premixed with dilutions of normal human globulins, normal rabbit serum, or immune rabbit serum. As predicted from the neutralizing titers of the serum pools from groups 2 and 3, the highest doses, 62.5 g and 25 g, respectively, protected the mice from 5 LD 50 s of ricin (or 2 g), whereas lower doses, at or below 12.5 g and 5.0 g, respectively, did not (data not shown).
Discussion
RiVax was developed based on our knowledge of the structurefunction relationships of ricin. As shown in Fig. 2A , RTA and ricin B chain are joined by a single disulfide bond (1, 4, 5) . Although the holotoxin inactivated by paraformaldehyde or by heat is immunogenic and protective, some residual toxicity remains (24) . Ricin B chain makes a poor vaccine in animals (25) , whereas RTA induces protective Abs (26) . As shown in Fig. 2B , RTA contains a ribotoxic site and a VLS-inducing site, either or both of which could cause toxicity when used as a vaccine. Because the key amino acid residues involved in its ribotoxic site (Y80, Y123, E177, R180, N209, and W211) (27) and the VLSinducing site (L74, D75, and V76) (19, 28) have been identified, a reasonable strategy for developing a safe vaccine was to introduce a single mutation into each site to produce a totally nontoxic RTA molecule. Based on the use of RTA-containing immunotoxins in humans, it is known that the major immunodominant linear B cell epitope and HLA-class II-restricted T cell epitopes involve regions close to or within the active site of RTA (L161-E185) (29, 30) . Furthermore, there is a second class II-restricted T cell epitope located at D124-G140 (31, 32) . Perturbations of the RTA sequences within these regions could alter immunogenicity. Hence, the Y80A͞V76M mutation in RiVax (15) should not impinge on either of these sites. Furthermore, the expressed protein should retain its tertiary structure and stability.
Having shown that RiVax could protect mice against an injected ricin challenge of 10 LD 50 s, that it was stable as a frozen preparation as formulated, and that a formal toxicology study in rabbits identified no side effects (14), we felt that it was important to prove that it could safely immunize humans.
We therefore designed this pilot trial to determine safety and immunogenicity at three different doses using the same (but not necessarily optimal) dose regimen as tested in mice and rabbits. The major findings to emerge from the study are as follows. (i) RiVax was safe in the 15 volunteers vaccinated. There were no grade 3 or 4 symptomatic toxicities. However, there were modest increases in CPK in seven individuals that were probably related to the i.m. injection, and a significant increase in one individual that, in our judgment, was not related to the vaccine. (ii) RiVax induced seroconversions in one of five individuals in the lowest dose group, four of five in the intermediate dose group, and five of five in the highest dose group. (iii) The anti-RTA titers of the seroconverters and the longevity of these titers were not related to the dose of vaccine given and were variable within each group. However, three volunteers had Abs in their sera 28 days after the second vaccination, and this might have rendered the third vaccination less effective. (iv) The 10 individuals who made anti-RTA Ab also made ricin-neutralizing Ab. The globulins from two pools of positive sera, mixed with ricin and injected into mice, protected them from ricin intoxication. An extrapolation of this result to the blood volume of humans suggests that these volunteers would be protected against an injected dose of ricin of 0.3-3.0 mg, or Ϸ1-to 10-fold the human LD 50 . (v) As was the case in rabbits, the total Ab titers did not predict the neutralizing Ab titers in any of the seroconverters. Interestingly, the individual whose third vaccination was delayed by 84 days had the highest titer of neutralizing Ab, suggesting that it might be useful to delay the third boost by several months as is often done with other vaccines (31) .
Taken together, our results suggest that this vaccine should be further developed by testing different dose regimens and by formulating the vaccine with adjuvant (20, 21, (32) (33) (34) (35) (36) . It also remains to be determined whether i.m. vaccination with RiVax will protect mice against lethal doses of ricin aerosols or ingested ricin, although all ricin vaccines thus far tested in animals protect against death by ricin aerosols (27, (37) (38) (39) . However, lung and gut damage could be major problems in humans and require different formulations and routes of immunization to induce mucosal immunity (11, 26, (40) (41) (42) (43) .
Although there have been numerous attempts to generate an effective vaccine against ricin, to our knowledge no recombinant vaccine has yet been tested in humans or approved for human use. There is concern that ricin toxoids and native RTA are too toxic to use as vaccines in humans and that ricin B chain does not appear to make an effective vaccine in animals (25) . Thus, in the last several years, two other recombinant vaccines have been generated and tested. A vaccine developed by Marsden et al. (27) consists of RTA with a peptide introduced into a surfaceexposed loop in RTA distal from the active site and designed to inhibit ribotoxic activity. Hence, there are no ''internal'' modifications, suggesting that its immunodominant epitopes should be preserved. This modified RTA had reduced ribotoxic activity and no toxicity in rats in vivo. This vaccine is protease-resistant and induces protective immunity in rats. It does, however, contain the native ribotoxic and VLS-inducing sites, and the retention of these sites might be problematic in humans. A vaccine reported by Olson et al. (5) has been designed to have enhanced stability because its hydrophobic sites have been eliminated. It consists of a large fragment of RTA (RTA ) that lacks ribotoxic activity because of disruption of the active site. The VLS-inducing site is still present. When injected into mice with or without adjuvant (5) or into primates (unpublished work), it protected them from lethal doses of ricin administered by injection or aerosol. Although this vaccine appears to have the advantage of improved stability, because of the extensive deletions in the structure, it remains to be determined how well it will induce protective immunity in humans because important epitopes might have been compromised. RiVax has the advantage of minimal alterations in structure and the retention of all of the epitopes defined by a panel of mAbs. The current formulation does, however, require storage at Ϫ70°C.
In conclusion, all three vaccines appear to be promising candidates with different advantages and drawbacks. All three confirm and extend a paradigm in vaccine design, i.e., that antitoxins do not necessarily have to block the binding of a toxin to a target cell to be effective, and might instead disrupt downstream pathways such as internalization and͞or intracellular toxicity. The mechanism by which these vaccines protect animals and humans remains to be determined. The data in this study suggest that RiVax, the first recombinant ricin vaccine to be tested in humans, is safe and effective and should be further explored vis-à-vis different dose regimens and formulations with adjuvant.
Materials and Methods
Preparation of the Vaccine. The vaccine was prepared and tested as described in refs. 14 and 15. Four different vaccine lots produced in our good manufacturing practice laboratory were used in the study. The manufacturing method and data supporting activity and stability were included in our investigational new drug application filed with the Food and Drug Administration and are reported in ref. 14.
Characterization of the Vaccine. Each lot of vaccine was fully characterized before release and use in the trial. The vaccine was vialed at 0.2 mg͞ml in PBS containing sucrose and Tween 80 and stored at Ϫ70°C. Stability was determined at monthly intervals by visual inspection, SDS͞PAGE, HPLC, and in vivo potency testing in mice (14) .
Measurement of Total Anti-RTA Abs in Human Sera. Ninety-six-well plates (Costar, Corning) were coated overnight at 4°C with 100 l of WT recombinant RTA or RiVax in 20 g͞ml in PBS. After washing and blocking the plates with 5% FCS, 100 l of human anti-RTA Ab (purified from serum obtained from a cancer patient who received RTA-containing immunotoxin and developed an immune response) at concentrations ranging from 1 to 1,000 ng͞ml (standard curve) or 100 l of normal serum or sera from vaccinated volunteers at appropriate dilutions were added in triplicate. After overnight incubation at 4°C, the plates were washed and [ 125 I]-labeled affinity-purified goat anti-human Ig (10 5 cpm͞100 l) was added. After a 2-h incubation at room temperature, the plates were washed again, and the radioactivity on the wells was counted in a gamma-counter (Amersham Pharmacia).
Measurement of Ricin-Neutralizing Abs in Human Sera. The sera that were positive by RIA were further tested for their ability to protect Daudi cells from ricin intoxication. Briefly, 10 5 cells per well were plated in a 96-well plate in serial dilutions in methionine-free media with immune or nonimmune serum (negative control) in the presence or absence of 5 ϫ 10 Ϫ10 M ricin, previously shown to be the IC 90 in this assay (able to inhibit protein synthesis by 90%). After overnight incubation, the cells were pulsed with [ 35 S]-L-methionine for 4 h, and the incorporated counts were determined. The averages of triplicate wells of samples with and without ricin were used to calculate the percent inhibition (%I) with the formula ΄ CPM͑ Ϫ ricin͒ Ϫ CPM͑ ϩ ricin͒ CPM͑ Ϫ ricin͒ ΅ ϫ 100 ϭ %I.
The percent protection was determined from each serum dilution percent relative to nonimmune serum percent as follows:
1 Ϫ ΄ %I serum dilution %I normal serum ΅ ϫ 100 ϭ %P.
The plot of %P vs. the log of the concentration of anti-RTA Ig (from the RIA above) was used to calculate the IC 50 concentration of neutralizing Ab. The lower the concentration of Ab necessary to neutralize ricin, the more potent the Ab and the higher the titer.
The Ability of Abs Against RTA in the Human Sera to Passively Protect Mice Against Ricin Intoxication. The sera with neutralizing Abs were tested for their ability to protect mice against ricin intoxication. Equal volumes of immune sera from seroconverters from dose groups 2 and 3 were pooled separately, and the Ab-containing globulins precipitated with 50% saturated ammonium sulfate. The precipitate was dissolved in PBS and dialyzed against PBS overnight at 4°C and concentrated. The anti-RTA and neutralization titers were determined by the RIA and cytotoxicity assays described above. Groups of mice were injected i.p. with various dilutions of this preparation, normal human globulins, normal or immune rabbit serum, or PBS, mixed with a 5ϫ LD 50 dose of ricin (50 ng͞g); dosing was based on the in vitro neutralization titers such that the highest dose was predicted to be protective, based on previous studies with rabbit immune sera and purified anti-vaccine Abs. Mice were monitored twice daily and killed when they had difficulty breathing or moving, usually within 24-48 h.
